上海莱士：“SR604注射液”新增适应症获得药物临床试验批准通知书

Core Viewpoint - Shanghai Laishi (002252) has received approval from the National Medical Products Administration for the clinical trial of SR604 injection, which is intended for the preventive treatment of bleeding episodes in patients with vascular hemophilia [1] Company Summary - The company announced the approval of a clinical trial for SR604 injection, expanding its application to include preventive treatment for vascular hemophilia patients [1]